title: Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer.
abstract: Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21(Waf/Cip1) and p27(Kip) expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21(Waf/Cip1) expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.
authors.affiliation: Graduate Institute of Medical Science, College of Medicine, Taipei Medical University, Taipei, Taiwan.
authors.forename: S
authors.initials: S
authors.lastname: Charoenfuprasert
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Yang
authors.forename: Y-C
authors.initials: YC
authors.lastname: Lee
authors.forename: K-C
authors.initials: KC
authors.lastname: Chao
authors.forename: P-Y
authors.initials: PY
authors.lastname: Chu
authors.forename: C-R
authors.initials: CR
authors.lastname: Lai
authors.forename: K-F
authors.initials: KF
authors.lastname: Hsu
authors.forename: K-C
authors.initials: KC
authors.lastname: Chang
authors.forename: Y-C
authors.initials: YC
authors.lastname: Chen
authors.forename: L-T
authors.initials: LT
authors.lastname: Chen
authors.forename: J-Y
authors.initials: JY
authors.lastname: Chang
authors.forename: S-J
authors.initials: SJ
authors.lastname: Leu
authors.forename: N-Y
authors.initials: NY
authors.lastname: Shih
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000502:physiology; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis / Q000502:physiology*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics; D005260:Female; D016391:Genes, src; D006801:Humans; D008297:Male; D051379:Mice; D010051:Ovarian Neoplasms / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D011494:Protein Kinases / Q000032:analysis / Q000502:physiology*
chemical_list: D000951:Antigens, Neoplasm; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D011494:Protein Kinases; C509079:SIK3 protein, human; D055372:AMP-Activated Protein Kinases